Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.

Participants needed: 355
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Avenzo Therapeutics, Inc.Updated: May 26, 2026Locations: 10
Eligibility criteria

Patient must be an adult, 18 years of age and older with an Eastern Cooperative... [+3]

Patients with active central nervous system (CNS) metastases are not eligible. P... [+6]

Read more
Status: Recruiting

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.

Participants needed: 480
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Avenzo Therapeutics, Inc.Updated: May 13, 2026Locations: 18
Eligibility criteria

Patient must be an adult, between 18 and 75 years of age with an Eastern Coopera... [+3]

Uncontrolled hypertension. [+6]

Read more
Status: Recruiting

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

Participants needed: 380
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Avenzo Therapeutics, Inc.Updated: May 4, 2026Locations: 14
Eligibility criteria

Male or female aged ≥ 18 years old at screening with Eastern Cooperative Oncolog... [+4]

Patients should not have received any prior selective investigational CDK (CDK2,... [+10]

Read more
Status: Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

Participants needed: 430
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Avenzo Therapeutics, Inc.Updated: Nov 19, 2025Locations: 13
Eligibility criteria

Male or female aged ≥18 years old at screening with Eastern Cooperative Oncology... [+4]

Received an investigational agent or anticancer therapy within 2 weeks, or 5 hal... [+10]

Read more